Cargando…
Therapeutic inhibition of MPO stabilizes pre-existing high risk atherosclerotic plaque
Currently there are no established therapies to treat high-risk patients with unstable atherosclerotic lesions that are prone to rupture and can result in thrombosis, abrupt arterial occlusion, and a precipitous infarction. Rather than being stenotic, rupture-prone non-occlusive plaques are commonly...
Autores principales: | Chen, Weiyu, Tumanov, Sergey, Kong, Stephanie M.Y., Cheng, David, Michaëlsson, Erik, Bongers, André, Power, Carl, Ayer, Anita, Stocker, Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663534/ https://www.ncbi.nlm.nih.gov/pubmed/36375379 http://dx.doi.org/10.1016/j.redox.2022.102532 |
Ejemplares similares
-
Near-Infrared Autofluorescence (NIRAF) in Atherosclerotic Plaque Dissociates from Intraplaque Hemorrhage and Bilirubin
por: Chen, Weiyu, et al.
Publicado: (2023) -
Serum MPO levels and activities are associated with angiographic coronary atherosclerotic plaque progression in type 2 diabetic patients
por: Chen, Qiujing, et al.
Publicado: (2022) -
LncRNAs as Regulators of Atherosclerotic Plaque Stability
por: Petkovic, Aleksa, et al.
Publicado: (2023) -
Angiogenesis in the atherosclerotic plaque
por: Camaré, Caroline, et al.
Publicado: (2017) -
Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling
por: Piek, Arnold, et al.
Publicado: (2019)